Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
35 Autoimmune Diseases Trials near Houston, TX
Power is an online platform that helps thousands of Autoimmune Diseases patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerVNS for Epilepsy
Houston, TexasVagal nerve stimulation is a neurosurgical procedure consisting of implantation of an impulse generator battery with leads placed into the vagus nerve in the neck. This procedure was FDA approved for epilepsy in the 1990s and is commonly performed as an outpatient surgery. The mechanism of action is not well understood; however it is increasingly recognized that electrical stimulation of the vagus nerve may impact other organ systems in the body including the immune and gastrointestinal systems. Concrete characterization of the peripheral effects of VNS in human gut microbiome and immune systems will: (1) elucidate peripheral mechanism of action of chronic VNS therapy, (2) identify peripheral preoperative biomarker of VNS efficacy, and (3) create a foundation for research investigating new GM and IM-related disease indications for VNS.
The primary objective of this study is to characterize the pre- and post-operative oral and gut microbiome of patients implanted with vagal nerve stimulator (VNS) for epilepsy. Secondary objectives of this study include: (1) to characterize the pre-operative and post-operative immune profile of patients undergoing VNS implantation for epilepsy, (2) to elucidate whether oral and/or gut microbiota changes are related to VNS efficacy for epilepsy and (3) identification of a biomarker predicting VNS efficacy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:0 - 60
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Infection, Cancer, Autoimmune, Others
Must Not Be Taking:Anticholinergics, Corticosteroids, Antiarrhythmics, Others
30 Participants Needed
Nivolumab for Cancer
Houston, TexasThis phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Chemotherapy, Radiotherapy, Allogeneic Transplant, Others
Must Not Be Taking:Anticancer Investigational Agents
300 Participants Needed
Satralizumab for Autoimmune Encephalitis
Houston, TexasThe purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12+
Sex:All
Key Eligibility Criteria
Disqualifiers:Cancer, Demyelinating Disease, HIV, Others
Must Not Be Taking:IL-6 Inhibitors, CD19 Antibodies
152 Participants Needed
AD-PluReceptor + Tafasitamab for Autoimmune Disorders
Houston, TexasThe goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN.
The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease.
The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pulmonary Disease, Cardiac Manifestations, CNS Pathology, Others
Must Not Be Taking:Rituximab, Voclosporin, Anifrolumab, Others
47 Participants Needed
Inebilizumab + Blinatumomab for Lupus
Houston, TexasThe main objective is to assess the safety and tolerability of inebilizumab in adult participants with active and refractory systemic lupus erythematosus (SLE) with nephritis (Subprotocol A) and to assess the safety and tolerability of subcutaneous (SC) blinatumomab in adult participants with active and refractory (SLE) with nephritis (Subprotocol B) and in adult participants with active refractory rheumatoid arthritis (RA) (Subprotocol C).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
110 Participants Needed
CNTY-101 for Lupus
Houston, TexasCALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:17+
Sex:All
Key Eligibility Criteria
Disqualifiers:Hemodialysis, CNS Disease, Transplant, Others
48 Participants Needed
CC-97540 for Severe Refractory Lupus
Houston, TexasThis trial is testing a new drug called CC-97540. It aims to help people with severe autoimmune diseases that don't get better with regular treatments. Researchers want to see if the drug is safe, how it moves through the body, and if it can improve patients' health.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Drug-induced SLE, Multiple Sclerosis, Psoriasis, Others
129 Participants Needed
Deucravacitinib for Lupus
Houston, TexasThis trial is testing a new medication called deucravacitinib to see if it is safe and effective for people with moderate to severe lupus, a disease where the immune system attacks the body. The medication aims to reduce inflammation by targeting specific enzymes in the immune system.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Drug-induced SLE, Other Autoimmune Diseases, Active Lupus Nephritis, Others
Must Be Taking:Immunosuppressant, Antimalarial
490 Participants Needed
Sibeprenlimab for Sjögren's Syndrome
Houston, TexasThis is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
80 Participants Needed
ESK-001 for Lupus
Houston, TexasThis trial is testing a new medication called ESK-001 to see if it can help adults with SLE, a chronic autoimmune disease. The study will check the effectiveness and safety of ESK-001 over several months.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Drug-induced SLE, Lupus Nephritis, Neuropsychiatric SLE, Others
Must Be Taking:Corticosteroids, Antimalarials, DMARDS
388 Participants Needed
MuSK-CAART for Myasthenia Gravis
Houston, TexasThis trial is testing a new cell therapy called MuSK-CAART for patients with a severe muscle disease known as MuSK myasthenia gravis. These patients have harmful antibodies that attack their muscles. The therapy uses special cells to find and stop these bad antibodies, potentially leading to long-term relief from the disease. Rituximab has been used to treat MuSK myasthenia gravis, showing some success in patients who are refractory to standard treatments.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Other Autoimmune Disorders, Others
Must Not Be Taking:Rituximab, Immunosuppressives, Others
24 Participants Needed
CABA-201 for Lupus
Houston, TexasThis trial tests a new cell therapy called CABA-201 for patients with active lupus. It aims to help those whose disease is not well-controlled by current treatments. Patients first get standard medications to prepare their bodies, then receive CABA-201 to help manage their immune system.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Infections, Organ Transplant, Others
12 Participants Needed
Belimumab for Interstitial Lung Disease
Houston, TexasInterstitial lung disease (ILD) is a lung condition resulting in inflammation and stiffening of the lung, often associated with connective tissue diseases (CTDs). ILD causes reduction in lung volume, shortness of breath, cough and fatigue therefore has high impact on quality of life and is also the leading cause of death in participants with these conditions. The study will assess whether treatment of CTD-ILD participants with belimumab in addition to standard therapy will result in the stabilization and/or improvement of lung function and improve symptoms associated with ILD with an acceptable safety profile.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Systemic Sclerosis, Rapidly Progressive Disease, Emphysema, Others
Must Be Taking:Standard Therapy
440 Participants Needed
HZN-1116 for Sjogren's Syndrome
Houston, TexasThe purpose of this study is to measure the efficacy and safety of HZN-1116 in participants with Sjogren's syndrome (SS).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:System Sclerosis, Active Malignancy, Pregnancy, Others
Must Not Be Taking:Biologics, B Cell Therapies
262 Participants Needed
SBT777101 for Hidradenitis Suppurativa
Houston, TexasThis study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Complex HS, Others
Must Be Taking:Systemic Therapy, Biologic Drug
24 Participants Needed
CABA-201 for Inflammatory Myopathies
Houston, TexasRESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:6 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Infections, Organ Transplant, Others
24 Participants Needed
Cenerimod for Systemic Lupus Erythematosus
Houston, TexasThis trial is testing cenerimod, a medication aimed at reducing symptoms of Systemic Lupus Erythematosus (SLE) in adults with moderate to severe symptoms. Researchers want to see if cenerimod can help when added to existing treatments. The medication works by calming the overactive immune system, which may reduce inflammation and other symptoms.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, CNS Lupus, Heart Disease, Others
Must Be Taking:Antimalarials, Mycophenolate, Azathioprine, Methotrexate
420 Participants Needed
Cenerimod for Systemic Lupus Erythematosus
Houston, TexasThe goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe symptoms of systemic lupus erythematosus.
The main questions it aims to answer are:
* Whether cenerimod causes any adverse effects ('side effects') when given on top of drugs already being given for systemic lupus erythematosus.
* How well cenerimod works to reduce symptoms of systemic lupus erythematosus when taken for at least 1 year and up to 3 years.
Participants taking part in this study will have already taken part in another study, where they received either cenerimod or placebo (look-alike substance containing no active drug) for 1 year.
In this clinical study approximately 680 participants will receive cenerimod (on top of drugs already being given for systemic lupus erythematosus) for at least 1 year and up to 3 years.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Age:18 - 75
Sex:All
680 Participants Needed
DSG3-CAART Cell Therapy for Pemphigus Vulgaris
Houston, TexasThis trial is testing new cell therapies for patients with pemphigus vulgaris who don't respond to standard treatments. The therapies involve modifying the patient's own immune cells to better fight the disease and potentially provide long-term relief.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Paraneoplastic Pemphigus, Active Malignancy, Others
Must Be Taking:Immunosuppressive Therapies
55 Participants Needed
Anifrolumab for Systemic Sclerosis
Houston, TexasThis trial is testing anifrolumab, an injectable medication, in adults with systemic sclerosis. The goal is to see if it can reduce immune system attacks to lessen symptoms and prevent further damage. Anifrolumab is a human monoclonal antibody that targets the type I interferon receptor and has been tested in multiple studies for systemic lupus erythematosus (SLE) and other autoimmune diseases.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Cardiopulmonary, Overlap Syndromes, Malignancy, Others
306 Participants Needed
CABA-201 for Myasthenia Gravis
Houston, TexasRESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Infections, Cardiac Impairment, Others
12 Participants Needed
Nerandomilast for Interstitial Lung Disease
Houston, TexasAdults 18 years of age and older or above legal age with lung fibrosis related to systemic autoimmune rheumatic disease can participate in this study. People can only take part if they show no improvement in lung function after standard treatment with immunosuppressant medicine. The main purpose of this study is to find out how a medicine called nerandomilast affects the lungs in people with systemic autoimmune rheumatic disease.
Participants are put into 2 groups randomly, which means by chance. One group takes nerandomilast tablets and the other group takes placebo tablets. Placebo tablets look like nerandomilast tablets but do not contain any medicine. Participants take a tablet 2 times a day for 26 weeks. Participants continue immunosuppressant treatment for their underlying rheumatic disease.
Participants are in the study for about 7.5 months. During this time, they visit the study site 8 times. At study visits, participants have lung function tests. At select visits, chest imaging is performed. Participants fill in questionnaires about their symptoms and quality of life. The results between the 2 groups are compared to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
Pivotal Trial
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
400 Participants Needed
This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pulmonary Hypertension, SSc Renal Crisis, Others
Must Be Taking:Mycophenolate, Methotrexate, Azathioprine
300 Participants Needed
Batoclimab for Thyroid Eye Disease
Houston, TexasThis is a 2-cohort (observational and treatment cohort) extension study for participants completing feeder studies (IMVT-1401-3201 or IMVT-1401-3202). The observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the efficacy of batoclimab as assessed by proptosis responder rate.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Surgery, Irradiation, Medical Therapy, Others
180 Participants Needed
Batoclimab for Graves' Eye Disease
Houston, TexasThis trial tests batoclimab, a medication given as weekly injections under the skin, to see if it can help reduce eye bulging in patients with proptosis. The treatment starts with a higher dose for a few months, followed by a lower dose for a few more months. Batoclimab works by adjusting the immune system to decrease inflammation and swelling around the eyes.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Age:18+
Sex:All
100 Participants Needed
The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells.
"Funding Source - FDA OOPD"
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:All
Sex:All
Key Eligibility Criteria
Disqualifiers:Uncontrolled Infection, Previous Allo-HCT, HIV/HTLV, Pregnancy, Others
39 Participants Needed
Ravulizumab for Neuromyelitis Optica Spectrum Disorders
Houston, TexasThe primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Age:18+
Sex:All
58 Participants Needed
Ianalumab for Autoimmune Diseases
Bellaire, TexasThe purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injection of 300 mg/2 mL auto-injector (AI) versus two injections of 150 mg/1 mL pre-filled syringe (PFS), and to evaluate the safety and tolerability of ianalumab following the s.c. administration of both devices in participants with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE).
A second optional cohort may be included with the objective of demonstrating the comparability of pharmacokinetics of ianalumab between 1 x 2 mL Pre-filled Syringe (PFS) and 2 x 1 mL PFS.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 70
Sex:All
Key Eligibility Criteria
Disqualifiers:Infections, Live Vaccines, Pregnancy, Others
140 Participants Needed
ALPN-101 for Lupus
Bellaire, TexasThis is Phase 2, multinational, randomized, blinded study to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacokinetics and pharmacodynamics of ALPN-101 (acazicolcept) in adults with moderate to severe active systemic lupus erythematosus (SLE)
Trial Details
Trial Status:Active Not Recruiting
Age:18 - 70
Sex:All
130 Participants Needed
Batoclimab for Graves' Eye Disease
Bellaire, TexasTo evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Optic Neuropathy, Autoimmune Diseases, Others
Must Not Be Taking:Steroids
100 Participants Needed
Page 1 of 2+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Autoimmune Diseases clinical trials in Houston, TX pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Autoimmune Diseases clinical trials in Houston, TX work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Autoimmune Diseases trials in Houston, TX 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Houston, TX for Autoimmune Diseases is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Houston, TX several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Autoimmune Diseases medical study in Houston, TX ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Autoimmune Diseases clinical trials in Houston, TX ?
Most recently, we added Nerandomilast for Interstitial Lung Disease, Inebilizumab + Blinatumomab for Lupus and Sibeprenlimab for Sjögren's Syndrome to the Power online platform.